Aim: A novel coumarin derivative 7-hydroxy-5-methoxy-4-methyl-3-(4-methylpiperazin-1-yl)-coumarin (IMM-H004) has shown antiapoptotic, anti-inflammatory and neuroprotective activities. In this study we investigated the effects of IMM-H004 on spatial memory in rats treated with okadaic acid (OKA), which was used to imitate Alzheimer's disease (AD)-like symptoms. Methods: SD rats were administered IMM-H004 (8 mg·kg -1 ·d
Introduction
Neurofibrillary tangles (NFTs), which are composed of intracellular filamentous aggregates of hyperphosphorylated tau protein, are one of the pathological hallmarks of Alzheimer's disease (AD). Thus reducing the amount of hyperphosphorylated tau protein might be a therapeutic strategy for treating AD. Previous studies revealed that down-regulation of protein phosphatases or up-regulation of protein kinases are the main causes for tau hyperphosphorylation. Protein phosphatase 2A (PP2A), a major tau phosphatase in the brain, is recognized as a promising candidate that may participate in the regulation of tau phosphorylation in AD [1] . Okadaic acid (OKA), a selective and potent inhibitor of PP2A, has been reported to induce AD-like hyperphosphorylation of tau [2] . Infusion of OKA into the rat brain causes severe memory impairments that are accompanied by remarkable neuropathological changes, including hippocampal neurodegeneration, a paired helical filament-like phosphorylation of tau, Aβ accumulation and neuronal apoptosis [2] [3] [4] [5] . It is known that AD patients and animal models of AD suffer from senile plaques, chronic inflammation and free radical damage. IMM-H004 [7-hydroxy-5-methoxy-4-methyl-3-(4-methylpiperazin-1-yl)-coumarin, Figure 1 ], a novel coumarin compound, has been reported to have neuroprotective effects, especially in neuronal injury resulting from Aβ proteins (β-amyloid, the main toxic component of senile plaque in brain of AD patients), lipopolysaccharides (LPS, the revulsive of inflammation) or oxygen glucose deprivation (OGD) [6] [7] [8] . Furthermore, IMM-H004 also attenuated spatial learning impairments resulting from transient global brain ischemia [9] . Therefore, it is important to systematically research the neuroprotective effects of IMM-H004 in AD. The present study www.chinaphar.com Song XY et al Acta Pharmacologica Sinica npg was designed to investigate in rats the effects of IMM-H004 on OKA-induced learning and memory deficits and the mechanisms associated with such effects.
Materials and methods

Reagents
The compound IMM-H004 (molecular formula: C 16 H 20 O 4 N 2 ; molecular weight: 304; chemical purity: 98%) was synthesized by Sphinx Scientific Lab Corporation (Tianjin, China). OKA, which was purchased from Sigma-Aldrich (St Louis, MO, USA), was dissolved in saline at a concentration of 40 ng/μL. Donepezil was obtained from the National Institutes for Food and Drug Control (Beijing, China).
Anti-tau, anti-p-tau (Ser396) and anti-β-amyloid primary antibodies were purchased from Abcam (Cambridge, UK). Anti-β-actin primary antibody was purchased from SigmaAldrich. Anti-rabbit IgG secondary antibody and anti-mouse IgG secondary antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Enhanced chemiluminescent substrate was obtained from Pierce (Rockford, IL, USA). The TdT-mediated dUTP nick-end labeling (TUNEL) staining kit was purchased from YEASEN Biotechnology Company (Shanghai, China).
Animals
Adult male Sprague-Dawley (SD) rats (220±20 g, 6-7 weeks old) were obtained from Vital River Laboratories of Beijing (Beijing, China). The rats were housed in a temperatureand light-controlled room (23 °C, 12-h light cycle) and had free access to food and water. All animals were handled in accordance with the standards established in the Guide for the Care and Use of Laboratory Animals published by the Institute of Laboratory Animal Resources of the National Research Council (USA) and approved by the Animal Care Committee of the Peking Union Medical College and the Chinese Academy of Medical Sciences.
Experimental design
The rats were randomly assigned to 5 groups (n=12). The groups and treatment conditions are detailed in Table 1 . The effective doses of OKA, IMM-H004 and donepezil were determined according to our previous studies [5, 9] . The total duration of the experimental period was 26 days (Figure 2A ). The rats were treated with IMM-H004, donepezil or double distilled water as a vehicle by intragastric (ig) administration once daily from d 1 to 25. On d 8 and 9, the rats were microinjected with OKA or saline into a lateral cerebral ventricle. One week after the microinjection, the rats were tested for spatial memory in the Morris water maze for 9 days ( Figure 2B , from d 17 to 25). On the last day of the experimental period (d 25) the rats were anesthetized and sacrificed by infusion into the aorta with 0.1 mol/L phosphate-buffered saline (PBS, pH 7.4) followed by 4% paraformaldehyde in PBS (for immunohistochemistry and TUNEL staining) or by decapitation (for Western blot).
Surgery and microinjection
Surgery was performed and a single intracerebroventricular (icv) injection was administered on either d 8 or 9. Each rat received only one microinjection. For the microinjections, rats were anesthetized with chloral hydrate (300 mg/kg, ip) and restrained in a stereotactic apparatus. OKA (200 ng in 5 μL saline) or saline (0.9% NaCl for medical use, 5 μL) was injected into the right lateral cerebral ventricle according to the following coordinates: 0.8 mm posterior to bregma, 1.5 mm lateral to the saggital midline, and 3.6 mm ventral to the dura. Microinjections were performed with a Hamilton micro syringe [10] over a period of 5 min (1 μL/min). After the microinjection, the needle was kept in place for an additional 5 min 
Morris water maze test
The Morris water maze test ( Figure 2B ) was used to evaluate spatial memory functioning following the treatment. The rats were trained in the Morris water maze by an experimenter who was blind to the treatment schedule (double blind). The water maze apparatus consisted of a metal circular pool (diameter 120 cm, height 80 cm), in which a circular Plexiglas platform (diameter 10 cm, height 40 cm) was hidden 1-2 cm below the surface of the water (24±1 °C). The maze was located in an experimental room that was maintained under stable conditions during the experiment. The task consisted of two consecutive stages: a learning stage and a reversal learning stage. Both stages included two tests, which were the orientation navigation (ON) and spatial probe (SP) tests.
In the first ON test (ON1) for the learning stage, rats were trained once daily for four consecutive days (from d 17 to 20) to swim to a hidden platform located in the middle of the 3rd quadrant. All tests began at 10:00. At the beginning of a session, each rat was placed in the water, facing the wall of the tank, and given a maximum time of 120 s to find the hidden platform. Once the rat reached the platform, it was allowed to stay on the platform for 30 s. During each trial, the time required to reach the hidden platform (escape latency) and swim paths were recorded. For the SP1 test, which was performed on d 21, the platform was removed from the tank, and the rats were allowed to swim for 120 s. The number of crossings through the previous platform location were recorded. In the reversal learning stage, rats were forced to find a new platform position [11] , which was moved to the middle of 2nd quadrant. The test procedures and parameters recorded were the same as those for the learning stage. ON2 was performed once daily from d 22 to 24, and SP2 was performed on d 25. Escape latency and crossing times through the platform locations were monitored by a computerized tracking system (Chinese Academy of Medical Sciences, Beijing, China).
Immunohistochemistry
On d 26, four rats chosen randomly from each group were deeply anesthetized with chloral hydrate (400 mg/kg, ip) and perfused with 0.1 mol/L PBS (pH 7.4) followed by 4% paraformaldehyde in PBS. Then, the brains were removed, fixed in the same fixative for 24 h, and then dehydrated and subsequently embedded in paraffin blocks. The brain tissues throughout the hippocampus were cut into 4-μm thick coronal sections for immunohistochemistry.
The paraffin slices were dewaxed with xylol twice to remove paraffin preservative and were hydrated using various concentrations of alcohol (100%, 100%, 95%, 85% and 75%) and distilled water. Then, the slices were incubated for 10 min at room temperature in 3% H 2 O 2 solution to reduce endogenous peroxidase activity and then washed with PBS. The samples were placed in 10% goat serum for 1 h at room temperature and incubated overnight at 4 °C with mouse anti-β amyloid or rabbit anti-p-tau primary antibody. Next, the slices were rinsed with PBS and exposed to anti-mouse or anti-rabbit IgG secondary antibody for 1 h at room temperature. After another rinse in PBS, slices containing β amyloid were counterstained with methyl green and then incubated briefly in 3,3'-diaminobenzidine (DAB) substrate (Zhongshan Goldenbridge Biotechnology, Beijing, China) to develop color, whereas slices containing p-tau were incubated briefly in DAB substrate. After a final wash with PBS, the slices were mounted on slides, dehydrated, cleared, and coverslipped with mounting medium.
Western blot analysis
On d 26, six rats were chosen randomly from each group to obtain samples of hippocampus tissue bilaterally for Western blot analysis. Specifically, the skull was opened to provide access to the brain. Then, cortical tissues were exposed bilaterally from the brain midline using forceps. The hippocampus was then identified and removed. The operation was performed at 4 °C, and the hippocampus tissues were stored at -80 °C until use. The hippocampus tissues were homogenized and dissociated with lysis buffer (50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, and protease inhibitor mixture) for 30 min and then centrifuged at 12 000×g for 30 min; the supernatants were collected after centrifugation [12] . Protein concentrations were determined using the BCA protein assay. Briefly, samples were separated by 10% SDS-PAGE and then transferred to PVDF membrane. The membranes were blocked with 3% bovine serum albumin in tris buffer and then incubated overnight at 4 °C with anti-p-tau (1:2000), anti-tau (1:1000), anti-β amyloid (1:500) or anti-β actin antibody (1:10 000). The membranes were again washed and incubated with secondary antibody (anti-rabbit IgG, 1:5000; anti-mouse IgG, 1:5000) for 1 h at room temperature. Finally, the bands were marked with enzyme-linked chemiluminescence and were detected using the enhanced chemiluminescence plus detection system (GE Healthcare, Fairfild, CT, USA). The density of each band was quantified using Quantity One analyzer software (Tokyo, Japan).
TUNEL staining TUNEL staining was performed for paraffin sections using an in situ cell death detection kit and according to the manufacturer's instructions. After dewaxing and aquation, slices were permeabilized in proteinase K (20 μg/mL) for 20 min at room temperature. The slices were then exposed to TdT equilibration buffer, Recombinant TdT Enzyme and Alexa Fluor 488-12-dUTP Labeling Mix for 60 min at 37 °C. Nuclear staining was identified in cell nuclei with DAPI. DNA breakage was imaged by fluorescence microscopy (Nikon, Tokyo, Japan). Six random non-overlapping sections were viewed and counted under a grid at 100× magnification. All tissue sections were labeled and viewed in a blinded manner and without knowledge of the experimental groups. 
Results
IMM-H004 attenuated spatial memory impairment
We evaluated the effects of IMM-H004 and confirmed that the spatial cognition of rats was impaired by the OKA injections by testing the rats' spatial learning abilities in the Morris water maze test (learning stage). In addition, we examined the rats' cognitive flexibility following IMM-H004 administration by relocating the platform in the Morris water maze test (reversal learning stage).
In the learning stage, from d 17 to 20, the escape latencies were recorded. A repeat measures ANOVA showed significant differences at different time points and between groups, but no significant difference was observed in the interaction Figure 3C ]. However, the decreased times were significantly increased by IMM-H004 administration (IMM-H004: P=0.011; donepezil: P=0.154). In addition, the swimming speed did not vary significantly among groups on d 21 (data not shown).
Comparable performances were also observed during reversal training, in which the hidden platform was moved to a new location. A repeated measures ANOVA for latency in the reversal learning stage revealed similar results as those for the learning stage. A multivariate ANOVA showed a significant difference on d 24 [F(4,51)=5.028, P<0.001, Figure 3D ]. However, this was significantly decreased in rats following IMM-H004 (P=0.004) or donepezil (P=0.015) administration, which Figure 3E ) showed increased times for crossing over the platform on d 25. Thus, in this experiment, the model rats showed clear deficits in spatial memory consolidation. IMM-H004-induced improvement in these deficits indicates that IMM-H004 plays a role in memory enhancement in a rat model of AD induced by OKA. The effect of limiting spatial memory deficits in reversal learning indicates that IMM-H004 or donepezil could improve cognitive flexibility in rats.
IMM-H004 reversed tau pathology
The effect of IMM-H004 on tau phosphorylation in the hippocampus was determined by immunohistochemistry and Western blotting. E178 antibody identifying tau Ser396 (the site is aberrantly hyperphosphorylated in NFTs) was used to observe the phosphorylation level of tau. As can be seen in Figure 4A , the OKA group showed weak staining of p-tau; however, overall staining of p-tau was stronger in OKAinjected rats compared with that in the sham group, suggesting that tau is hyperphosphorylated after OKA injection. However, IMM-H004 and donepezil administration in rats significantly reversed these alterations. Furthermore, the level of tau phosphorylation, as measured by Western blot analysis [F(4,25)=10.616, P<0.001, Figure 4B , 4C], revealed that phosphorylation of tau was significantly increased compared to that in the sham group (P<0.001), but it was reversed by IMM-H004 (P=0.001) or donepezil (P=0.034) administration. Western blot analysis showed that IMM-H004 significantly reduced OKA-induced tau phosphorylation, which was consistent with the results of the immunohistochemistry analysis. These result indicated that IMM-H004 or donepezil could reverse the tau pathology induced by OKA. 
IMM-H004 inhibited apoptosis
We used TUNEL staining to detect apoptosis in the hippocampus [F(3,20)=13.484, P<0.001, Figure 6A , 6B]. TUNELpositive cells, which were stained with green fluorescence, were not detected in the sham group. However, many cells in the OKA groups were stained with green fluorescence. Nuclei were stained by DAPI with blue fluorescence. Treatment with IMM-H004 (P=0.001) or donepezil (P=0.007) significantly decreased the number of TUNEL-positive cells. This result indicated that IMM-H004 could inhibit apoptosis in the hippocampus. In addition, the location where strong TUNEL staining was identified the same location where weak staining with p-tau and strong staining with Aβ were identified in the OKA group.
Discussion
Memory impairments have been induced in animal models through microinjection of OKA into the brain [5, 13] . In the present study, unilateral icv injection of OKA induced spatial memory impairments, which is consistent with previous studies [5] . IMM-H004 has been shown to ameliorate spatial learning performance in global ischemia [9] , and to inhibit Aβ-induced neuronal apoptosis [6, 9] . Thus, IMM-H004 might be used to improve memory impairment in AD patients. Therefore, further investigation is necessary. In the present study, donepezil, which is a cholinesterase inhibitor that could improve memory in AD animals and patients, was used as a positive control, and we investigated whether IMM-H004 could inhibit OKA-induced memory impairments and its underlying mechanisms.
The Morris water maze test is often used to test the spatial memory ability of animals. The findings of our study demonstrated that rats administered 8 mg/kg IMM-H004 or 1 mg/kg donepezil performed similarly as the sham rats did during the learning stage of the Morris water maze test. Thus, IMM-H004 or donepezil treatment reversed spatial memory impairments induced by OKA in rats. The type of learning and memory tested by stable platform paradigms is arguably rare in humans because humans must continually build upon previous memories within a similar context. The Morris water maze task, in which the platform is relocated over time, might challenge learning and memory [14] . We therefore used a platform relocation water maze experiment to explore whether IMM-H004 can affect cognitive flexibility in rats that received an icv injection of OKA. The results indicated that IMM-H004 or donepezil improved the rats' performance in response to challenges in learning and memory by shortening the escape latency and increasing their crossing frequency in the right quadrant, where the platform was previously located. Hence, IMM-H004 improved cognitive flexibility and may attenuate spatial memory injury.
Tau is a phosphoprotein that plays a crucial role in microtubule assembly and stability [15] . The aberrantly hyperphosphorylated tau in the AD brain leads to disruption of the neuronal cytoskeleton and axonal transport [16] . Additionally, abnormal hyperphosphorylation also makes tau resistant to proteolytic degradation, which leads to its gradual accumulation in the cell and promotes the formation of NFTs [17] . In this study, the immunohistochemistry and Western blot analyses showed that OKA induced unusual tau hyperphosphorylation in the hippocampus. However, IMM-H004 administration decreased the level of p-tau, which contributed to an improved biological activity of tau in promoting the assembly and maintaining the stability of the microtubules, as well as preventing the formation of NFTs.
Senile plaques that induce extracellular Aβ aggregation is another pathological characteristic of AD [18] . The neurotoxicity of Aβ has been shown in vitro [6, 19] and in vivo [20, 21] . Aβ, tau and their associated signaling pathways represent important therapeutic targets for AD. Furthermore, Aβ inhibits degradation of hyperphosphorylated tau by proteasomes [22] . However, the relationship between tau and Aβ, and which one of these two proteins is the primary cause of AD, remain unclear. Currently, a growing body of work supports the notion that Aβ regulates the phosphorylation of tau to accelerate NFT formation [18] . Additionally, the hyperphosphorylation of tau protein increases the accumulation of Aβ and decreases its degradation [4, 23] . In the present study, we found that icv injection of OKA increased Aβ expression, which is consistent with previous reports [3, 4] . Both immunohistochemistry and Western blot results showed that treatment with IMM-H004 downregulated OKA-induced Aβ formation in the hippocampus.
OKA (200 ng) icv microinjection induced spatial memory impairments, as well as apoptosis in the CA1 region of the hippocampus. IMM-H004 or donepezil administration significantly attenuated the OKA-induced increase in the number of apoptotic cells. Therefore, the beneficial effects of IMM-H004 on OKA-induced spatial memory impairments in rats may be subsequent to its attenuating effects on OKA-induced apoptosis in hippocampal cells.
The hippocampus plays a critical role in learning and memory, and the most important parts for learning and memory in the hippocampal regions are the CA1, CA3 and dentate gyrus regions [24] . Our results demonstrated that an icv injection of OKA increased the unusual phosphorylation of tau in the hippocampus. Moreover, OKA treatment also led to a significant accumulation of Aβ in CA1. These results indicated that the changes observed in the CA1 region of the hippocampus may contribute to the decline in memory observed in AD. Therefore, IMM-H004 may prevent spatial learning and memory decline resulting from an icv injection of OKA by decreasing Aβ formation and the level of p-tau in the CA1 region.
As Figure 4A , 5A, and 6A showed, the locations for weak p-tau staining were the same locations for strong Aβ and apoptotic cell staining in the OKA group. Therefore, OKA (200 ng) icv injection first induced tau hyperphosphorylation, which further increased the Aβ burden and apoptosis.
In this study, the positive control, which was the cholinesterase inhibitor donepezil, could also decrease hyperphosphorylation of tau, β-amyloid plaques and apoptosis. These results were similar to those obtained with IMM-H004. Kamat et al indicated that donepezil could improve OKA-induced memory damage by increasing PP2A expression [25] , which decreased hyperphosphorylation of tau, or by increasing cholinergic function [26] . Noh et al [27] showed that donepezil improved Aβ1-42-induced neurotoxicity through activation of PP2A, which could decrease hyperphosphorylation of tau. Furthermore, donepezil could attenuate Aβ-associated mitochondrial dysfunction and reduce mitochondrial Aβ accumulation in vivo and in vitro, which might differ from its previously reported effect on AChE [28] . Our previous study [5] indicated that donepezil could ameliorate OKA-induced hyperphosphorylation of tau and Aβ accumulation. Therefore, donepezil improved OKA-induced neurotoxicity possibly through PP2A activation or by improving cholinergic functioning. However, the upstream target of IMM-H004 that resulted in reversed tau and Aβ pathology is still unclear and requires further investigation. In conclusion (Figure 7 ), unilateral icv microinjection of OKA significantly induced spatial memory impairments, caused hyperphosphorylation of tau protein, and increased the Aβ burden and apoptosis in the hippocampus of rats. Administration of IMM-H004 effectively attenuated OKAinduced apoptosis and spatial memory impairments. These effects were likely mediated through two possible mechanisms: (1) IMM-H004 stabilized the tau pathology, which further decreased the Aβ content; and (2) IMM-H004 attenuated Aβ accumulation. These findings suggest that IMM-H004 may have therapeutic effects in the treatment of cognitive impairments and neuropathological changes that occur in AD and other neurodegenerative diseases. 
